Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer

W. Akerley, H. Choy

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A phase I trial of paclitaxel therapy, administered as a weekly 3-h infusion for 6 weeks with concurrent daily thoracic radiation to patients with advanced or medically inoperable non-small cell lung cancer, was performed. Paclitaxel was escalated in increments of 10 mg/m2/week in successive cohorts of three new patients as tolerated, starting at 10 mg/m2/week. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks), followed by a boost to the primary tumor (20 Gy in 2 weeks). Twenty-seven patients entered this study through seven dose levels of paclitaxel ranging from 10-70 mg/m2/week for the primary purpose of evaluating the toxicity of concurrent chemoradiation treatment. Esophagitis was the principal and dose-limiting toxicity. Radiation pneumonitis occurred in two patients. Other toxicities were mild. Although not designed as an efficacy study, 23 patients were available for response, and an overall response rate of 74% (confidence interval, 65-83%) was observed.

Original languageEnglish (US)
JournalLung Cancer
Volume12
Issue numberSUPPL. 2
DOIs
StatePublished - 1995

Fingerprint

Paclitaxel
Non-Small Cell Lung Carcinoma
Thorax
Radiation
Radiation Pneumonitis
Esophagitis
Neoplasms
Lymph Nodes
Confidence Intervals
Therapeutics

Keywords

  • Lung cancer
  • Paclitaxel
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. / Akerley, W.; Choy, H.

In: Lung Cancer, Vol. 12, No. SUPPL. 2, 1995.

Research output: Contribution to journalArticle

@article{b2447d3ca43b4100b4d3f359537e7221,
title = "Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer",
abstract = "A phase I trial of paclitaxel therapy, administered as a weekly 3-h infusion for 6 weeks with concurrent daily thoracic radiation to patients with advanced or medically inoperable non-small cell lung cancer, was performed. Paclitaxel was escalated in increments of 10 mg/m2/week in successive cohorts of three new patients as tolerated, starting at 10 mg/m2/week. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks), followed by a boost to the primary tumor (20 Gy in 2 weeks). Twenty-seven patients entered this study through seven dose levels of paclitaxel ranging from 10-70 mg/m2/week for the primary purpose of evaluating the toxicity of concurrent chemoradiation treatment. Esophagitis was the principal and dose-limiting toxicity. Radiation pneumonitis occurred in two patients. Other toxicities were mild. Although not designed as an efficacy study, 23 patients were available for response, and an overall response rate of 74{\%} (confidence interval, 65-83{\%}) was observed.",
keywords = "Lung cancer, Paclitaxel, Radiotherapy",
author = "W. Akerley and H. Choy",
year = "1995",
doi = "10.1016/0169-5002(95)00426-2",
language = "English (US)",
volume = "12",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer

AU - Akerley, W.

AU - Choy, H.

PY - 1995

Y1 - 1995

N2 - A phase I trial of paclitaxel therapy, administered as a weekly 3-h infusion for 6 weeks with concurrent daily thoracic radiation to patients with advanced or medically inoperable non-small cell lung cancer, was performed. Paclitaxel was escalated in increments of 10 mg/m2/week in successive cohorts of three new patients as tolerated, starting at 10 mg/m2/week. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks), followed by a boost to the primary tumor (20 Gy in 2 weeks). Twenty-seven patients entered this study through seven dose levels of paclitaxel ranging from 10-70 mg/m2/week for the primary purpose of evaluating the toxicity of concurrent chemoradiation treatment. Esophagitis was the principal and dose-limiting toxicity. Radiation pneumonitis occurred in two patients. Other toxicities were mild. Although not designed as an efficacy study, 23 patients were available for response, and an overall response rate of 74% (confidence interval, 65-83%) was observed.

AB - A phase I trial of paclitaxel therapy, administered as a weekly 3-h infusion for 6 weeks with concurrent daily thoracic radiation to patients with advanced or medically inoperable non-small cell lung cancer, was performed. Paclitaxel was escalated in increments of 10 mg/m2/week in successive cohorts of three new patients as tolerated, starting at 10 mg/m2/week. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks), followed by a boost to the primary tumor (20 Gy in 2 weeks). Twenty-seven patients entered this study through seven dose levels of paclitaxel ranging from 10-70 mg/m2/week for the primary purpose of evaluating the toxicity of concurrent chemoradiation treatment. Esophagitis was the principal and dose-limiting toxicity. Radiation pneumonitis occurred in two patients. Other toxicities were mild. Although not designed as an efficacy study, 23 patients were available for response, and an overall response rate of 74% (confidence interval, 65-83%) was observed.

KW - Lung cancer

KW - Paclitaxel

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029001101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029001101&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(95)00426-2

DO - 10.1016/0169-5002(95)00426-2

M3 - Article

C2 - 7551942

AN - SCOPUS:0029001101

VL - 12

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 2

ER -